buparvaquone has been researched along with Toxoplasmosis, Animal in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdel Shafi, IR; Abdel-Aal, AA; Afife, AA; Esmat, M; Fahmy, MEA; Hassan, SI; Shaheen, HAA; Shalaby, MA | 1 |
| Aguado-Martínez, A; Barrett, LK; Choi, R; Ferre, I; Hemphill, A; Hulverson, MA; Maly, DJ; McCloskey, MC; Moreno-Gonzalo, J; Müller, J; Ojo, KK; Ortega-Mora, LM; Van Voorhis, W | 1 |
2 other study(ies) available for buparvaquone and Toxoplasmosis, Animal
| Article | Year |
|---|---|
The superior efficacy of chloroquine over buparvaquone in reducing the chronic cerebral Toxoplasma gondii cysts load and improving the ultrastructural pathology in an immunocompromised murine model.
Topics: Animals; Chloroquine; Cysts; Disease Models, Animal; Mice; Spiramycin; Toxoplasma; Toxoplasmosis, Animal; Toxoplasmosis, Cerebral | 2023 |
Development of a murine vertical transmission model for Toxoplasma gondii oocyst infection and studies on the efficacy of bumped kinase inhibitor (BKI)-1294 and the naphthoquinone buparvaquone against congenital toxoplasmosis.
Topics: Animals; Antiprotozoal Agents; Disease Models, Animal; Female; Infectious Disease Transmission, Vertical; Male; Mice; Naphthalenes; Naphthoquinones; Piperidines; Pyrazoles; Toxoplasmosis, Animal; Toxoplasmosis, Congenital; Treatment Outcome | 2017 |